Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Thierry Façon, Meletios Α. Dimopoulos, Xavier P Leleu, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 17, pp. 1597-1609
Closed Access | Times Cited: 55

Showing 1-25 of 55 citing articles:

Multiple myeloma: 2024 update on diagnosis, risk‐stratification, and management
S. Vincent Rajkumar
American Journal of Hematology (2024) Vol. 99, Iss. 9, pp. 1802-1824
Open Access | Times Cited: 49
Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial
Frida Bugge Askeland, Einar Haukås, Tobias S. Slørdahl, et al.
The Lancet Haematology (2025) Vol. 12, Iss. 2, pp. e120-e127
Closed Access | Times Cited: 2
Evaluating Minimal Residual Disease Negativity as a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta‐Analysis of Randomized Controlled Trials
Ioannis Ntanasis‐Stathopoulos, Charalampos Filippatos, Anastasios Ntanasis‐Stathopoulos, et al.
American Journal of Hematology (2025) Vol. 100, Iss. 3, pp. 427-438
Open Access | Times Cited: 1
The Burden of Multiple Myeloma in China: Trends from 1990 to 2021 and Forecasts for 2050
Xuelin Dou, Guangcai Duan, You Zhong, et al.
Cancer Letters (2025) Vol. 611, pp. 217440-217440
Closed Access | Times Cited: 1
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins
Paola Neri, Noémie Leblay, Holly Lee, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 8, pp. 590-609
Closed Access | Times Cited: 7
Novel Treatment Options for Multiple Myeloma
Andrew J. Portuguese, Rahul Banerjee, Gui Zhen Chen, et al.
JCO Oncology Practice (2025)
Closed Access
Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carfilzomib and anti-CD38 monoclonal antibodies
Luciano J. Costa, Francesca Gay, Ola Landgren, et al.
Annals of Hematology (2025)
Open Access
Isatuximab-Based Therapy for Multiple Myeloma
Thierry Façon
New England Journal of Medicine (2025) Vol. 392, Iss. 5, pp. 518-520
Closed Access
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of atezolizumab for alveolar soft part sarcoma, epcoritamab for follicular lymphoma, and isatuximab for multiple myeloma in Japan
Noriomi Matsumura, Masaki Mandai
International Journal of Clinical Oncology (2025)
Closed Access
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma
Meletios A. Dimopoulos, Peter M. Voorhees, Fredrik Schjesvold, et al.
New England Journal of Medicine (2024)
Closed Access | Times Cited: 4
Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse
Cyrille Touzeau, Xavier Leleu, Mourad Tiab, et al.
British Journal of Haematology (2025)
Closed Access
Blurring the Lines: Beyond Using Transplant Eligibility to Guide Induction Therapy in Myeloma
Darren Pan, Anupama Kumar, Alfred Chung, et al.
The Hematologist (2025) Vol. 22, Iss. 2
Open Access
Immuntherapien des multiplen Myeloms
Sofie‐Katrin Kadel, Leo Rasche
Deleted Journal (2025)
Closed Access
Practical Considerations for Early Relapsed/Refractory Multiple Myeloma in the Canadian Landscape in 2024
Cinthia Wan Ting Phua, Sylvia McCulloch
Canadian Hematology Today (2025)
Closed Access
Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice Use in Canada
Hira Mian, Alissa Visram, Steven Chun-Min Shih, et al.
Clinical Lymphoma Myeloma & Leukemia (2025)
Open Access
Minimal Residual Disease Significance in Multiple Myeloma Patients Treated with Anti-CD38 Monoclonal Antibodies
Federico Caroni, Vincenzo Sammartano, Paola Pacelli, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 159-159
Open Access
Efficacy and safety of anti-CD38 monoclonal antibodies-based therapy versus standard therapy in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis
Muhammad Osama, Muhammad Haris Khan, Sharib Raza Khan, et al.
Therapeutic Advances in Hematology (2025) Vol. 16
Open Access
Multiple Myeloma: Improved Outcomes Resulting from a Rapidly Expanding Number of Therapeutic Options
Susanna Kim, Adam ElSayed, Jonathan E. Moore, et al.
Targeted Oncology (2025)
Closed Access
Optimising quadruplet regimens to broaden eligibility in multiple myeloma
Tanya M. Wildes
The Lancet Haematology (2025) Vol. 12, Iss. 2, pp. e87-e88
Closed Access
Risk of Synchronous and Second Primary Malignancies in Patients with Newly Diagnosed Multiple Myeloma Transplant-Ineligible Treated with Lenalidomide
Thomas Systchenko, Laly Nsiala, Arthur Bobin, et al.
(2025)
Closed Access
Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study
Saad Z. Usmani, Thierry Façon, Vânia Hungria, et al.
Nature Medicine (2025)
Open Access
The Evolving Landscape in Multiple Myeloma: From Risk Stratification to T Cell-Directed Advanced Therapies
Carmen Besliu, Alina Tănase, Ionela Rotaru, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 525-525
Open Access
European Myeloma Network Group Review and Consensus Statement on Primary Plasma Cell Leukemia
Pellegrino Musto, Monika Engelhardt, Niels W.C.J. van de Donk, et al.
Annals of Oncology (2025)
Closed Access
Therapie des multiplen Myeloms – was ist neu und was bleibt?
K. Martin Kortüm, Johannes M. Waldschmidt, Hermann Einsele
Deleted Journal (2025)
Closed Access
Current State of Evidence on Definitions and Management of High-Risk Multiple Myeloma
Bhavesh Mohan Lal, Frits van Rhee, Samer Al Hadidi
Current Oncology Reports (2025)
Closed Access
Page 1 - Next Page

Scroll to top